L26/O-281 Systematic gene–disease assessment and whole exome sequencing in women with unexplained infertility
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von J. Applebaum und 13 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Do women with unexplained infertility carry rare variants in genes previously implicated in oocyte or early embryo defects? Summary answer Variants in validated genes implicated in oocyte and early embryo competency are common among women with unexplained infertility. What is known already Unexplained infertility is diagnosed after standard evaluation excludes ovulatory, anatomic, endocrine, and male factor causes. This diagnosis of exclusion likely reflects heterogenous biological defects, including subtle gamete dysfunction, impaired fertilization, early embryonic arrest, or altered endometrial receptivity. Rare Mendelian variants in genes controlling meiosis, oocyte activation, maternal-effect pathways, and zona pellucida structure have been reported. However, most implicated genes derive from cases in isolated families or small, mono-ethnic cohorts and lack systematic gene-disease validity assessment or evaluation in broadly recruited clinical populations. Consequently, the contribution of oocyte and early embryo competency genes on unexplained infertility remains poorly defined. Study design, size, duration This investigation comprised two components: (i) a systematic literature review with gene curation and a validated gene–disease assessment and (ii) a prospective multicenter cohort study conducted from July 2021 to March 2023 enrolling 979 women with unexplained infertility who underwent whole exome sequencing. Ovarian hyperstimulation cycle phenotypic data encompassing egg retrieval, embryologic, and embryo transfer outcomes were available for 668 participants across 2,298 cycles. Participants/materials, setting, methods Candidate oocyte and early embryo competency genes were identified from systematic literature review. Gene-disease relationships were classified as strong, moderate, limited, or absent using a validated algorithm integrating published probands, variant pathogenicity, functional assays, and animal models. Women with unexplained infertility were recruited from Mass General Brigham fertility clinics, Boston IVF, community-based advertisements, and the Reproductive Medicine Network’s AMIGOS trial. Whole exome sequencing was performed. Cycle outcomes were abstracted for participants undergoing ovarian hyperstimulation. Main results and the role of chance Gene–disease validity assessment identified 84 candidate genes, including 36 (42.8%) classified as strong and 17 (20.2%) as moderate. Strong and moderate genes clustered into biological pathways, including meiotic spindle assembly (TUBB8, KIF11, TACC3, HAUS6), cell-cycle checkpoints (WEE2, CDC20, FBXO43), meiotic recombination (MEI4, REC114), DNA damage response (BRCA1/2, MLH3, CHEK1), zona pellucida integrity (ZP1-3, ASTL), and maternal-effect programs supporting early embryogenesis (BTG4, NLRP2/5/7, PADI6, TLE6). Among 979 women with unexplained infertility (mean age 32.6 ± 3.6 years; BMI 25.6 ± 5.6 kg/m²; AMH 2.9 ± 2.8 ng/mL), 747 variants at a minor allele frequency under one percent were detected in 52 of 53 strong or moderate genes. 685 (91.7%) were missense, 28 (3.7%) frameshift, 19 (2.5%) premature stop, and 16 (2.0%) splice site variants. 678 (69.3%) carried at least one variant and 329 (33.6%) carried multiple variants. Most variants were monoallelic, with three homozygous (PATL2, CHEK2, BRCA2) and 44 compound heterozygous genotypes (PAD15, ZFP36L2, MEI4, KPNA7, FBXO43, HAUS6, INCENP, TUBA1C, BRCA1/2, MLH3, REC114, NLRP2/5/7, PABPC1L). Women with any loss-of-function variant demonstrated lower oocyte maturity rates versus non-carriers (74.6% versus 80.6%, p = 0.033). No differences were observed in fertilization, blastocyst development, clinical pregnancy, or live birth rates between variant carriers and non-carriers. Limitations, reasons for caution Attributing the cohort’s infertility phenotypes directly to identified variants is limited by uncertain pathogenicity of missense variants, predominately monoallelic findings, uncharacterized male partner genotypes, and possible unrecognized endometriosis. Wider implications of the findings These findings establish a rigorously curated genomic framework for women with unexplained infertility, reframing a diagnosis of exclusion as potentially genetically driven. These findings may inform future diagnostic panels, genetic counseling, mechanistic studies, and precision, individualized fertility care. Trial registration number No
Zitieren
APA
Applebaum, J., Plummer, L., Bryant, N., Asp, E., Stureborg, V., Barlow, K., Venis, J., Salnikov, K., Petrozza, J., Smith, K. K., Sakkas, D., Balasubramanian, R., Lippincott, M., & Seminara, S. (2026). L26/O-281 Systematic gene–disease assessment and whole exome sequencing in women with unexplained infertility. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.279
Vancouver
Applebaum J, Plummer L, Bryant N, Asp E, Stureborg V, Barlow K, et al. L26/O-281 Systematic gene–disease assessment and whole exome sequencing in women with unexplained infertility. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.279
BibTeX
@article{Applebaum2026,
author = {Applebaum, J. and Plummer, L. and Bryant, N. and Asp, E. and Stureborg, V. and Barlow, K. and Venis, J. and Salnikov, K. and Petrozza, J. and Smith, K. Keefe and Sakkas, D. and Balasubramanian, R. and Lippincott, M. and Seminara, S.},
title = {L26/O-281 Systematic gene–disease assessment and whole exome sequencing in women with unexplained infertility},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.279}
}
EUVIMED